ascopubs.org

The absolute oral bioavailability (BA) of 150-mg and bioequivalence (BE) of six 25- and one 150-mg erlotinib (E) tablets, a small molecule inhibitor of the epidermal growth ...

A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data ...
FierceBiotech

Xceleron and Crystal Pharmatech Announce Partnership to Improve Early Clinical Development Utilizing Absolute Bioavailability Trials and Solid-State Solutions

GERMANTOWN, Md.--Xceleron, a U.S.-based leader in the application of ultra-sensitive analytical technology to novel clinical designs, has announced a partnership that will offer drug developers early ...
C&EN

In The Search For New Drugs, Diverging Roads For Microdosing

When microdosing was the next big thing—back in the early to mid-2000s—drug developers had great plans for it. One of the problems with drug development is that failures often happen late in the ...
ascopubs.org

Absolute bioavailability, mass balance, elimination route, and metabolite profile of the selective oral MEK1/2 inhibitor pimasertib in cancer patients.

Comparable pharmacokinetics of 85 mg RightSize nilotinib (XS003) and 150 mg Tasigna in healthy volunteers using a hybrid nanoparticle-based formulation platform for protein kinase inhibitors. This is ...